U.S. Department of Health & Human Services
National Institutes of Health
NCATS
This repository is under review for potential modification in compliance with Administration directives.
Dismiss
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
Donanemab
1ADB65P1KK
US Approved Rx (2024)
First approved in 2024
General
Names
8
Identifiers
7
Subunits
4
Related Substances
1
Donanemab
1ADB65P1KK
US Approved Rx (2024)
First approved in 2024
General
Approval Year
2024
711
Names
8
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
LY 3002813
Preferred Name
English
Donanemab
Official Name
English
LY-3002813
Code
English
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APP (AMYLOID BETA A4 PRECURSOR PROTEIN) A BETA 3-PYROGLUTAMYL PEPTIDES, A.BETA. 3 (3-X)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-444) (VH (HOMO SAPIENS IGHV1-3*01 (84.7%)-(IGHD)-IGHJ4*01 (
Systematic Name
English
DONANEMAB [USAN]
Common Name
English
Showing 1 to 5 of 8 entries
Previous
1
2
Next
Identifiers
7
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
CAS
1931944-80-7
PRIMARY
INN
10922
PRIMARY
SMS_ID
300000005929
PRIMARY
WIKIPEDIA
Donanemab
PRIMARY
USAN
LM-184
PRIMARY
Showing 1 to 5 of 7 entries
Previous
1
2
Next
Subunits
4
Subunit 0
>SUBUNIT_0
Subunit 1
>SUBUNIT_1
Subunit 2
>SUBUNIT_2
Subunit 3
>SUBUNIT_3
Related Substances
1
ACTIVE MOIETY
1ADB65P1KK
Donanemab
